Detailed price information for Theralase Technologies Inc. (TLT-X) from The Globe and Mail including charting and trades.
Herpes simplex virus partially liquefies the tightly packed, gel-like interior of human cell nuclei to copy itself faster, a ...
Herpes simplex virus partially liquifies the tightly packed, gel-like interior of human cell nuclei to copy itself faster, a new study shows.
Pritelivir, an investigational antiviral for herpes simplex virus, demonstrated strong efficacy in a phase 3 trial, with 62.7 ...
Nivedita Pujari, a postdoctoral researcher at Albert Einstein College of Medicine, studies how herpes simplex virus uses ...
Ongoing research aims to confirm the mechanism by which ICP4 fluidizes the nucleus, which could indicate specific targets to ...
Inhibiting the herpes simplex virus type 1 viral enzyme uracil-DNA glycosylase reactivates the natural defense protein apolipoprotein B mRNA editing enzyme, catalytic polypeptide-1 (APOBEC1) in the ...
– ABI-5366 is currently being evaluated in ongoing Phase 1b clinical trial with interim proof-of-concept data expected in fall 2025 – SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results